2-Year Expanded Efficacy Data From the GATHER2 Trial:
Advances in Dry AMD:
“2-Year Expanded Efficacy Data From the GATHER2 Trial”
The GATHER2 trial provided two-year expanded efficacy data on the investigational treatment for geographic atrophy secondary to age-related macular degeneration. The treatment involves avacincaptad pegol (ACP), which is an inhibitor of the C5 protein in the immune system. The results demonstrated sustained improvements in visual function and a significant reduction in lesion growth compared to the control group. Over the two years, patients receiving the treatment exhibited a meaningful preservation of vision, with a favorable safety profile. These findings underscore the potential of the therapy to provide long-term benefits for individuals affected by this progressive retinal disease.
Khanani AM, Patel SS, Staurenghi G, Tadayoni R, Danzig CJ, Eichenbaum DA, Hsu J, Wykoff CC, Heier JS, Lally DR, Monés J, Nielsen JS, Sheth VS, Kaiser PK, Clark J, Zhu L, Patel H, Tang J, Desai D, Jaffe GJ; GATHER2 trial investigators. Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial. Lancet. 2023 Oct 21;402(10411):1449-1458. doi: 10.1016/S0140-6736(23)01583-0. Epub 2023 Sep 8. PMID: 37696275.